Global Cementless Total Knee Arthroplasty (KA) Market is Segmented By Product Type (Mobile Bearing, Fixed Bearing), By End User (Hospitals, Specialty Clinics, Others), and By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Cementless Total Knee Arthroplasty Market is estimated to grow at a CAGR of 21.8% during the forecast period 2024-2031
A cemented joint prosthesis is made by using fast-drying bone cement to help affix it to the bone. It is also called a press-fit prosthesis and is specially textured to allow the bone to grow onto it and adhere to it over time.
Market Summary
| Metrics | Details |
| Market CAGR | 21.8% |
| Segments Covered | By Product Type, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more insights - Download the Sample
Market Dynamics
The rising incidence of arthritis in people and the increasing number of sports injuries will drive the cementless total knee arthroplasty (KA) market
The rising incidence of arthritis in people will drive the cementless total knee arthroplasty (KA) market
Worldwide, the annual incidence of RA is approximately 3 cases per 10,000 population, and the prevalence rate is around 1%, increasing with age and peaking between the ages of 35 and 50 years.
An autoimmune inflammatory disease that is progressive and shows systemic manifestations is known as rheumatoid arthritis. The course of this type of arthritis varies greatly from mild, even self-limiting disease to a severe, destructive variant that progresses rapidly. It invades the knee joint in more than about 90% of patients with long-term rheumatoid arthritis. Since recent improvements in total knee arthroplasty (TKA), the procedure has been performed in many patients to ameliorate the pain in the knee joint and the recovery of its function, and good follow-up results have been reported.
Because of the initial stability of the fixation and long-term durability of the components total knee arthroplasty (TKA) using a cemented technique has been recommended in patients with rheumatoid arthritis. However, similar long-term follow-up results have been reported in patients who have undergone cementless TKA.
The increasing number of sports injuries will drive the cementless total knee arthroplasty (KA) market
An estimated 8.6 million sports injuries that occur each year were reported by the U.S. Department of Health and Human Services. Around one-third of all sports injuries occur in a sports facility, playground, or athletic field.
Young patients have a higher demand for stresses on implants. Cementless fixation in TKA has become more popular because it is associated with long-term survival, particularly in younger patients. Previous studies reported that cementless fixation could achieve a physiological bond between bone and implant, resulting in prolonged survival from aseptic loosening. Even though, it has not been widely accepted in the field of joint surgery evidence of osteolysis has also been shown with cementless implants.
The EngageTM Partial Knee system offers porous implants for promoting biological fixation on both the tibia and femur. The 3-D printed Tibial Tray features the patented Engage™ Anchor technology that provides immediate stability at the tibial interface and the titanium Affinium3D™ ultra-porous bone ingrowth surface that promotes long-term cementless biological fixation.
Disadvantages related to body composition analyzers will hamper its market
Complications in TKA can be many like patellar fracture and subluxation, component loosening, stress-shielding, metal corrosion, local and systemic exposure to metal ions, and failure of bone growth, and many of these have different rates depending on the technique used. As many as 20 percent of TKA patients may be unsatisfied with their outcome. However, the revision surgery should not be performed unless the failure mechanism is understood and can be corrected. Even though the long-term success of knee replacements, failure does occur. Common causes of knee arthroplasty failure include instability, infection, aseptic loosening, polyethylene wear with or without particle disease (osteolysis), and extensor mechanism failure. Infection and instability are the most common causes of early failure (< 2 years after initial surgery). More than two years after primary implantation, the most common causes of failure are polyethylene wear and aseptic loosening.
The dreaded complication of a total joint replacement is deep periprosthetic infection. After TKA, the prevalence of deep infection is around 0.4–2.0%. The most common organisms are Staphylococcus epidermidis (25–30%) and Staphylococcus aureus (50–65%).
COVID-19 Impact on Market
Hospitals and medical practices have been affected during the COVID-19 pandemic due to several protocols. The cementless total knee arthroplasty (KA) procedures involved in this pandemic have been affected. As people are scared to undergo cementless total knee arthroplasty (KA) surgery due to the risk of COVID-19, there has been an impact on the total knee arthroplasty (KA) market.
Market Segment Analysis
The mobile bearing (MB) segment will dominate the market
As an alternative to fixed bearing (FB) implants the mobile bearing (MB) concept in total knee arthroplasty (TKA) was developed to reduce wear and improve range of motion (ROM), especially focused on younger patients. It offers the potential advantage of self-correcting the rotational mismatch between the tibia and the femur, providing optimization of patellofemoral mechanics and a potential reduction of related complications, including anterior knee pain and patellar clunk syndrome. The advantages of the mobile-bearing TKA are minimizing component loosening and minimizing polyethylene wear. The MB insert enhances the compatibility of FEM/INS in extension and during a squatting activity, the amount of INS/TIB rotation is significantly smaller than that of FEM/INS.
Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, announced U.S. Food and Drug Administration 510(k) clearance of the ROSA® Partial Knee System for robotically-assisted partial knee replacement surgeries.
The hospital segment will dominate the total knee arthroplasty (KA) market
Hospitals with their large scale, strong financial capabilities, and a broad range of services will see an increase in this segment. Hospitals provide the best surgeons, healthcare facilities, and advanced treatment options. Knee replacement surgery has become more advanced. If the patient is healthy, it can be done as an outpatient procedure without a hospital stay. If done in the hospital, expect to stay in the hospital for at least 1 to 4 days. Hence, this segment will dominate the market.
Market Geographical Share
North America will dominate the market
Rising awareness levels and developed healthcare infrastructure will rise the market in this region. Surgeons carry out approximately 600,000 total knee replacements annually in the United States.
MCRA announced that its client THINK Surgical has obtained clearance from the US Food and Drug Administration (FDA) to market the TSolution One Total Knee Application for use in total knee arthroplasty (TKA) in the United States. Pixee Medical, a pioneer in digitally augmented surgery technology, announces that its Knee+ AR computer-assisted orthopedic solution has received 510(k) clearance from the U.S. Food and Drug Administration.
Companies and Competitive Landscape
Major key players in DePuy Synthes, GROUP FH ORTHO, Smith & Nephew, Stryker, Zimmer Biomet, B. Braun Melsungen AG, Zhengzhou YKinspection Enterprise Co., Ltd., Chongqing Xishan Science & Technology Co., Ltd, and Guangzhou Lety Medical Limited
Key Companies to Watch
DePuy Synthes
Overview: DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, offers the world’s most comprehensive portfolio of orthopedic and MedTech solutions to Keep People Moving. With a strong portfolio of products,data-enabled solutions, and pairing people-centric care, DePuy Synthes delivers connected, innovative care. This legacy of innovation is both their heritage and future, rooted in reimagining orthopedics, strengthened by the expertise and reach of Johnson & Johnson.
Product Portfolio: DePuy Synthes solutions, specialties include joint reconstruction, trauma, craniomaxillofacial, spinal surgery, and sports medicine. In addition to the VELYS™ Digital Surgery portfolio, is designed to advance patient care. It delivers clinical and economic value to healthcare systems worldwide.
Key Development: On Jan. 19, 2021, The Johnson & Johnson Medical Devices Companies announced that DePuy Synthes received 510(k) clearance from the U.S. FDA for the VELYS™ Robotic-Assisted Solution. It is designed for use with the ATTUNE® Total Knee System and its clear indications for use and will become part of the broader VELYS Digital Surgery Platform of connected technologies.
Why Purchase the Report?
- Visualize the composition of the cementless total knee arthroplasty (ka) market segmentation By Product Type and End-User highlighting the key commercial assets and players.
- Identify commercial opportunities in the cementless total knee arthroplasty (ka) market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of cementless total knee arthroplasty (ka) market- level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
The cementless total knee arthroplasty (ka) market report would provide access to an approx. 53 market data tables, 41 figures, and 200 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
